Document Type : original article

Authors

1 Neonatal Research Center, Shiraz University of Medical Science, Shiraz, Iran

2 Department of Pediatrics, Shiraz University of Medical Science, Shiraz, Iran

3 Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

4 Department of pharmacology, Faculty of Veterinary Medicine, University of Tehran, Iran

5 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

6 University of Arizona, Tucson, AZ 85721, USA

10.22038/ijp.2023.70914.5212

Abstract

Background: Antihistamines are the most common drugs used for treating allergic rhinitis. They, significantly, reduce nasal symptoms by blocking the action of a chemical cytokine called histamine.  This study aimed to compare cetirizine and desloratadine's efficacy and adverse effects in children with allergic rhinitis.
Method: This randomized single-blinded clinical trial was conducted on 400 children with allergic rhinitis, aged 6-12 between February and September 2022. The patients were randomized to receive cetirizine or desloratadine for four weeks. We recorded the symptoms and adverse effects at the baseline and four weeks after starting the intervention.
Results: A total of 248 patients completed the study: 109 patients (47 female, 62 male) in the cetirizine group and 139 patients (53 female, 86 male) in the desloratadine group. The scores related to symptoms of allergic rhinitis before starting the drugs and after 4-week therapy were not significantly different between the two treatment groups (p= 0.1, p= 0.7, respectively). Cetirizine had more side effects than desloratadine in the treated patients (p = 0.02).
Conclusion: This study showed that cetirizine and desloratadine improved symptoms of children with allergic rhinitis; however, there was no significant difference in the efficacy of these two drugs.  Desloratadine caused fewer side effects in patients after 4 weeks of treatment.

Keywords

  1. Kalmarzi RN, Ataee P, Fathollahpour A, Behzadifar M, Moradi M, Sharifian F, Kalani N, Kooti W. The Prevalence of Allergic Rhinitis among Iranian Children: A Systematic Review and Meta-Analysis. Endocr Metab Immune Disord Drug Targets. 2020; 20(2):189-97.
  2. Akhouri S, House SA. Allergic Rhinitis. 2021 Mar 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30844213.
  3. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol. 2001; 108(1 Suppl):S9-15.
  4. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001; 108(1 Suppl):S2-8.
  5. Moghtaderi M, Hejrati Z, Kolahi N, Heidari B. Sensitization to aeroallergens in patients with allergic rhinitis, asthma, and atopic dermatitis in Shiraz, Southwestern Iran . Indian J Allergy Asthma Immunol 2015; 29:79-83
  6. American Academy of Allergy, Asthma & Immunology. Task force on allergic disorders promoting best practice: raising the standard of care for patients with allergic disorders. Executive summary report. 1998:1– 15.
  7. Kim H, Bouchard J, Renzi PM. The link between allergic rhinitis and asthma: a role for antileukotrienes ?. Can Respir J. 2008; 15(2):91-8.
  8. Kawauchi H, Yanai K, Wang DY, Itahashi K, Okubo K. Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Non Sedative Properties. Int J Mol Sci. 2019 8; 20(1):213.
  9. Portnoy JM, Dinakar C. Review of cetirizine hydrochloride for the treatment of allergic disorders. Expert Opin Pharmacother. 2004; 5 (1): 125–35.
  10. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med. 2015; 29; 372(5):456-63.
  11. McClellan K, Jarvis B. Desloratadine. Drugs. 2001; 61(6):789-96; discussion 797.
  12. Agrawal DK. Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin Investig Drugs. 2001; 10(3):547-60.
  13. Tassinari P, Suárez NR, Centeno J, Velásquez JV, Aguirre-Mariscal H, Gonzálezdíaz SN, Córdova Jerves AFd, LA Desloratadine Study Group. Desloratadine therapy improves allergic rhinitis symptoms in latin american children aged 6 to 12 years. World Allergy Organ J. 2009; 2(4):42-8.
  14. Simons FE, Prenner BM, Finn a Jr; Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003; 111(3):617-22.
  15. Adham TM. Treatment of allergic rhinitis with desloratadine: results of a multinational observational study in the Middle East gulf region. World Allergy Organ J. 2011; 4(8):130-4.
  16. Zhou P, Jia Q, Wang Z, Zhao R, Zhou W. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis. Front Pediatr. 2022; 25; 10:940213.
  17. Benazzo M, Leonardi S, Corsico A, Licari A, Miraglia Del Giudice M, Peroni D, Salpietro C, Marseglia GL, Ciprandi G. Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: a pilot study. Acta Biomed. 2020; 17; 92(1):e2021003.
  18. Purohit A, Melac M, Pauli G, Frossard N. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol. 2004; 92(6):635-40.
  19. Sukkul A, Ruxrungtham K. Comparison of efficacy of once daily Zyrtec (cetirizine), cetrizin (cetirizine), desloratadine and placebo: suppressive effects on allergen and histamine induced wheal and flare responses in allergic rhinitis patients. JACI. 2006; 11. 284.
  20. Juliana J, Evalina R, Irsa L, Loebis M. Efficacy comparison of cetirizine and loratadine for allergic rhinitis in children. Paediatr lndones. 2012; 52:61-6.
  21. Naqvi A, Gerriets V. Cetirizine. [Updated 2022 Nov 27]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.